Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dynavax Technologies Corp (NASDAQ: DVAX) closed the day trading at $12.01 up 2.74% from the previous closing price of $11.69. In other words, the price has increased by $2.74 from its previous closing price. On the day, 1.44 million shares were traded. DVAX stock price reached its highest trading level at $12.0851 during the session, while it also had its lowest trading level at $11.51.
Ratios:
For a better understanding of DVAX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 69.64. For the most recent quarter (mrq), Quick Ratio is recorded 12.34 and its Current Ratio is at 13.23. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on February 01, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 31 ’24 when CANO FRANCIS sold 3,615 shares for $11.93 per share. The transaction valued at 43,127 led to the insider holds 36,905 shares of the business.
Burgess Justin sold 20,526 shares of DVAX for $262,322 on Mar 01 ’24. The Chief Accounting Officer now owns 0 shares after completing the transaction at $12.78 per share. On Jan 04 ’24, another insider, Janssen Robert, who serves as the SVP and CMO of the company, sold 1,500 shares for $15.00 each. As a result, the insider received 22,500 and left with 49,925 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1578774528 and an Enterprise Value of 1027302848. As of this moment, Dynavax’s Price-to-Earnings (P/E) ratio for their current fiscal year is 92.17, and their Forward P/E ratio for the next fiscal year is 47.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.05 while its Price-to-Book (P/B) ratio in mrq is 2.31. Its current Enterprise Value per Revenue stands at 3.939 whereas that against EBITDA is -632.965.
Stock Price History:
Over the past 52 weeks, DVAX has reached a high of $15.01, while it has fallen to a 52-week low of $9.74. The 50-Day Moving Average of the stock is 5.12%, while the 200-Day Moving Average is calculated to be 3.57%.
Shares Statistics:
Over the past 3-months, DVAX traded about 2.28M shares per day on average, while over the past 10 days, DVAX traded about 3932010 shares per day. A total of 131.46M shares are outstanding, with a floating share count of 130.91M. Insiders hold about 0.42% of the company’s shares, while institutions hold 103.57% stake in the company. Shares short for DVAX as of 1730332800 were 18843277 with a Short Ratio of 8.27, compared to 1727654400 on 17043685. Therefore, it implies a Short% of Shares Outstanding of 18843277 and a Short% of Float of 17.52.
Earnings Estimates
The dynamic stock of Dynavax Technologies Corp (DVAX) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.03, with high estimates of $0.03 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.2 and $0.18 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.34, with 2.0 analysts recommending between $0.41 and $0.26.
Revenue Estimates
5 analysts predict $71.71M in revenue for the current quarter. It ranges from a high estimate of $74.1M to a low estimate of $68.47M. As of the current estimate, Dynavax Technologies Corp’s year-ago sales were $55.6MFor the next quarter, 5 analysts are estimating revenue of $68.05M. There is a high estimate of $68.09M for the next quarter, whereas the lowest estimate is $68M.
A total of 5 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $279.3M, while the lowest revenue estimate was $273.68M, resulting in an average revenue estimate of $276.94M. In the same quarter a year ago, actual revenue was $232.28MBased on 5 analysts’ estimates, the company’s revenue will be $331.89M in the next fiscal year. The high estimate is $345.6M and the low estimate is $321.29M.
